Montorsi W, Doldi S B, Klinger R, Montorsi F
Int Surg. 1986 Apr-Jun;71(2):84-6.
The results of jejunoileal bypass for morbid obesity were studied in 192 operated patients. Mean weight loss was 39.3% of initial weight and 80.5% of overweight. Medical benefits (such as improved glucose tolerance, lowered blood pressure, healed Pickwick syndrome, etc.) were maintained during the follow-up (average five years). The most feared complication of the jejunoileal bypass is severe hepatic failure, which appeared in 2.3% of the cases, only after the end-to-end jejunoileal bypass, and never more than 12 months after surgery. Most patients had satisfactory and lasting results due to a careful and assiduous postoperative follow-up, and to the strict co-operation between the medical staff and the patient. Medical therapy in the preoperative period was useful to control the weight gain by administration of a hypocaloric definite diet. In the postoperative period, we usually got benefits for the bypass induced intestinal malabsorption by administration of supportive vitamins and electrolytes. To prevent liver diseases we often found intestinal-specific antibiotics, aminoacidic solutions, hyperproteical diet and anti-steatosis agents helpful.
对192例接受空肠回肠分流术治疗病态肥胖症的患者的结果进行了研究。平均体重减轻为初始体重的39.3%，超重部分的80.5%。在随访期间（平均五年），医学益处（如改善糖耐量、降低血压、治愈匹克威克综合征等）得以维持。空肠回肠分流术最可怕的并发症是严重肝衰竭，其发生率为2.3%，仅在端端空肠回肠分流术后出现，且从不超过术后12个月。由于术后进行了仔细且勤勉的随访，以及医护人员与患者之间的严格合作，大多数患者取得了满意且持久的效果。术前进行医学治疗通过给予低热量固定饮食来控制体重增加是有用的。在术后阶段，我们通常通过给予支持性维生素和电解质来改善分流引起的肠道吸收不良。为预防肝脏疾病，我们经常发现肠道特异性抗生素、氨基酸溶液、高蛋白饮食和抗脂肪变性药物有帮助。
